Please use this identifier to cite or link to this item:
Title: Use of renin-angiotensin system antagonists post-PCI is associated with lower mortality in patients with reduced and preserved left ventricular (LV) function.
Author: Prosser, H.
Dinh, D.
Roberts, L.
Chandrasekhar, J.
Brennan, A.
Duffy, S.
Oqueli, Ernesto
Reid, C.
Clark, D.
Ajani, A.
Sebastian, M.
Freeman, M.
Teh, A.
Issue Date: 2020
Conference Name: 68th Cardiac Society of Australia and New Zealand Annual Scientific Meeting, the International Society for Heart Research Australasian Section Annual Scientific Meeting and the 14th Annual Australia and New Zealand Endovascular Therapies Meeting
Conference Date: December 11-13
Conference Place: Online
Abstract: Background: Guidelines support prescribing angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II-receptor blockers (ARBs) post-PCI in patients with LV dysfunction, diabetes and hypertension. Guidelines are based on older trials, and with advancements in PCI evidence investigating the long-term effects of ACEi/ARB use in patients with reduced and preserved ejection fraction (EF) post-PCI is lacking. Methods and Results: 21,388 patients with ACS from the Melbourne Interventional Group registry that underwent PCI (2005-2018) and alive at 30day follow-up were reviewed. At follow-up 83.8% were on ACEi/ARBs, and were comparably younger (mean age 63.5 vs 64.6years, p=0.001), included less men (74.2% vs 77.5%, p=0.001), had greater mean BMI (28.6 vs 27.4, p=0.001), hypertension (60.8% vs 52.2%, p=0.001), and lower prevalence of prior MI (17.3% vs 19.6%, p=0.001). Overall, those who had a STEMI (53.6% vs 41.1%, p=0.001) were more likely, while those with NSTEMI less likely to receive an ACEi/ARB (46.4% vs 58.9%, p=0.001). Overall, ACEi/ARB use was associated with a significant reduction in mortality (15.0% vs 22.7%; p<0.001; mean follow-up 5.5years). Sub-group analysis revealed ACEi/ARBs provide a mortality benefit across reduced and preserved EF (Figure). Conclusion: Prescribing of ACEi/ARBs post-PCI is high, and associated with significantly reduced mortality in both reduced and preserved LV function, ACEi/ARBs should be considered for all patients post-PCI regardless of LV function.
Internal ID Number: 01645
Type: Conference
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.